The FDA approval of Journavx is a positive regulatory milestone for Vertex, but the drug's adoption is hindered by several factors. The variable efficacy compared to opioids, competition from generics, and established prescriber habits limit its near-term market potential. The minimal benefit shown in the Phase 2 trial raises doubts about the previously estimated $11B peak sales, and the ongoing diabetic neuropathy trial's success is uncertain. These factors contribute to a tempered outlook for Vertex's short-term stock performance.